| Age (y), mean (range) |
22 (16-32) |
32 (19-51) |
32 (22-44) |
| Gender (no. female) |
6 |
4 |
6 |
| Race (no. Caucasian) |
11 |
14 |
9 |
|
Genotype (n)
|
|
|
|
| delta F508/delta F508 |
7 |
7 |
|
| delta F508/G551D |
1 |
2 |
|
| delta F508/Q98X |
1 |
0 |
|
| delta F508/1717→A |
1 |
0 |
|
| delta F508/2184delA |
0 |
1 |
|
| delta F508/G549N |
0 |
1 |
|
| E60X/621+1 G→T |
2 |
2 |
|
| Unknown |
2 |
2 |
|
|
Length of Inpatient stay (days, st dev)
|
16 (2) |
|
|
|
Baseline FEV1 % (st dev)
|
60 (23) |
|
|
|
Admission FEV1 % (st dev)
|
46 (22) |
|
|
|
Discharge FEV1 % (st dev)
|
54 (27) |
|
|
|
Admission Total Nasal Symptom Score (st dev)
|
3.2 (1.9) |
0.5 (1.0) |
1.3 (1.2) |
|
Discharge Total Nasal Symptom Score (st dev)
|
1.9 (2.3) |
|
|
|
Admission Nasal Physical Exam Score (st dev)
|
6.9 (4.0) |
3.8 (2.6) |
2.3 (1.5) |
|
Discharge Nasal Physical Exam Score (st dev)
|
7.9 (2.3) |
|
|
|
Microbiology (no. subjects)
|
|
|
|
|
Pseudomonas aeruginosa
|
9 |
11 |
|
|
Burkholderia cepacia
|
2 |
2 |
|
| MRSA |
11 |
11 |
|
|
Controller Medications (no. subjects)
|
|
|
|
| Nebulized Tobramycin |
11 |
7 |
|
| Azithromycin |
11 |
5 |
|
| Nebulized Colistin |
6 |
5 |
|
| Dornase alfa |
10 |
9 |
|
| Nebulized Hypertonic Saline |
1 |
3 |
|
|
Co-morbidities (no. subject)
|
|
|
|
| Pancreatic Insufficiency |
13 |
12 |
|
| Diabetes Mellitus |
10 |
5 |
|
| Sinus Disease |
12 |
10 |
|
| Liver Disease |
4 |
0 |
|
